Glafabra develops cell‑based gene therapies for enzyme deficiency disorders such as Fabry, Gaucher, and Pompe disease. Their platform delivers a durable, repeatable outpatient treatment that eliminates the need for frequent enzyme infusions, demonstrated by five Fabry patients who have remained infusion‑free for five years. The company has completed a pilot trial in Canada and is preparing IND filing and U.S. trials for late 2027.
Funding
Funding not disclosed
Founders
Product
Problem
Patients with enzyme deficiency disorders such as Fabry, Gaucher, and Pompe disease require lifelong biweekly enzyme replacement infusions, which are burdensome, costly, and provide only temporary symptom control. The need for frequent clinic visits reduces quality of life and limits treatment adherence.
Solution
Glafabra is developing a cell‑based gene therapy that delivers a functional copy of the missing enzyme via a durable, repeatable outpatient procedure. The approach uses engineered cells to produce the therapeutic enzyme continuously, eliminating the need for regular infusions. Clinical proof‑of‑concept has been demonstrated in five Fabry patients, achieving up to five years of freedom from biweekly dosing. A pilot trial in Canada is complete, and the company plans to file an IND in early 2027 with U.S. trial initiation later that year. The therapy aims to provide long‑term disease modification while simplifying the treatment regimen for patients and clinicians.
Target Audience
Primary customers are patients with Fabry, Gaucher, Pompe, and related lysosomal enzyme deficiency disorders, as well as specialty physicians and treatment centers that manage these rare metabolic diseases.
Features
- Autologous or allogeneic cell platform engineered to express the deficient enzyme continuously
- Outpatient administration eliminates the need for inpatient hospitalization
- Durable therapeutic effect demonstrated for up to five years in early clinical data
- Scalable manufacturing process designed for repeatable dosing across multiple enzyme deficiency indications
- Regulatory pathway supported by completed pilot trial and planned IND filing in Q1 2027